Journal of Cardiovascular Development and Disease (May 2023)
Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
- Satoshi Yamashita,
- Atsushi Sakamoto,
- Satoshi Shoji,
- Yoshitaka Kawaguchi,
- Yasushi Wakabayashi,
- Masaki Matsunaga,
- Kiyohisa Suguro,
- Yuji Matsumoto,
- Hiroyuki Takase,
- Tomoya Onodera,
- Kei Tawarahara,
- Masahiro Muto,
- Yasutaka Shirasaki,
- Hideki Katoh,
- Makoto Sano,
- Kenichiro Suwa,
- Yoshihisa Naruse,
- Hayato Ohtani,
- Masao Saotome,
- Tsuyoshi Urushida,
- Shun Kohsaka,
- Eisaku Okada,
- Yuichiro Maekawa
Affiliations
- Satoshi Yamashita
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- Atsushi Sakamoto
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- Satoshi Shoji
- Department of Cardiology, Hino Municipal Hospital, Hino 1910062, Japan
- Yoshitaka Kawaguchi
- Department of Cardiology, Seirei Mikatahara Hospital, Hamamatsu 4338558, Japan
- Yasushi Wakabayashi
- Department of Cardiology, Seirei Mikatahara Hospital, Hamamatsu 4338558, Japan
- Masaki Matsunaga
- Department of Cardiology, Iwata City Hospital, Iwata 4388550, Japan
- Kiyohisa Suguro
- Department of Cardiology, Fujinomiya City Hospital, Fujinomiya 4180076, Japan
- Yuji Matsumoto
- Department of Cardiology, Kikugawa City Hospital, Kikugawa 4390022, Japan
- Hiroyuki Takase
- Department of Internal Medicine, Enshu Hospital, Hamamatsu 4300929, Japan
- Tomoya Onodera
- Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka 4208630, Japan
- Kei Tawarahara
- Department of Cardiology, Hamamatsu Red Cross Hospital, Hamamatsu 4348533, Japan
- Masahiro Muto
- Department of Cardiology, Hamamatsu Medical Center, Hamamatsu 4328580, Japan
- Yasutaka Shirasaki
- Shirasaki Clinic, Kuki 3460031, Japan
- Hideki Katoh
- Department of Cardiology, Kosai General Hospital, Kosai 4310431, Japan
- Makoto Sano
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- Kenichiro Suwa
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- Yoshihisa Naruse
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- Hayato Ohtani
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- Masao Saotome
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- Tsuyoshi Urushida
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- Shun Kohsaka
- Department of Cardiology, Keio University School of Medicine, Tokyo 1608582, Japan
- Eisaku Okada
- Department of Faculty of Social Policy and Administration, Hosei University, Tokyo 1028160, Japan
- Yuichiro Maekawa
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
- DOI
- https://doi.org/10.3390/jcdd10050204
- Journal volume & issue
-
Vol. 10,
no. 5
p. 204
Abstract
Background: The guideline-recommended low-density lipoprotein cholesterol target level of p = 0.498). The two groups showed no significant differences in hospitalization for worsening heart failure and adverse events. Conclusions: In ACS patients who underwent PCI, short-term PCSK9 antibody therapy with conventional LLT was feasible in this pilot clinical trial. Long-term follow-up in a larger scale clinical trial is warranted.
Keywords
